Home › Compare › TCIIF vs ABBV
TCIIF yields 0.63% · ABBV yields 3.09%● Live data
📍 TCIIF pulled ahead of the other in Year 7
Combined, TCIIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TCIIF + ABBV for your $10,000?
Tracsis plc, together with its subsidiaries, provides software and hardware products, and consultancy services for the rail industry. The company operates in two segments, Rail Technology and Services; and Data, Analytics, Consultancy & Events. The Rail Technology & Services segment provides a suite of operational software products covering timetabling, resource and rolling stock planning and optimization, real time performance and control, service recovery, retail services, incident management, retail services, and asset management; and infrastructure software services that include safety management, planning and delivery of work, remote condition monitoring and data acquisition, and asset virtualization/intelligent infrastructure/digital railway. This segment also offers transit and ticketing solutions, including passenger analytics, retail operations, and delay repay. The Data, Analytics, Consultancy & Events segment provides informatics and location analytics, which include geographical information systems, data visualization and analytics platforms, and asset management; transport data and analytics, such as passenger/traffic data collection, and traffic insights covering data visualization and data-as-a-service; and event traffic management solutions, such as event transport planning and traffic management, and integrated traffic data management and event access control. It serves transport operators, transport authorities, infrastructure operators, government agencies and local authorities, as well as event organizers in the United Kingdom, Ireland, rest of Europe, North America, and internationally. The company was incorporated in 2004 and is headquartered in Leeds, the United Kingdom.
Full TCIIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.